Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02851563 · ClinicalTrials.gov registry record
A Natural History Study of Canavan Disease
A clinical trial of Canavan Disease, sponsored by NYU Langone Health.
- Completed
- Registry status
- 21
- Enrollment target
- 3
- Study locations
NCT02851563: Completed study of Canavan Disease, sponsored by NYU Langone Health.
NCT02851563 is a study of Canavan Disease that has completed, run by NYU Langone Health. The registered enrollment target is 21 participants. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02851563, a study of Canavan Disease, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to learn more about the natural history of Canavan disease
Conditions Studied
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
New York
- NYU Langone Medical Center - New York
Other
- University Medical Center Hamburg-Eppendorf - Hamburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-04 |
What the finished NCT02851563 record still lists
NCT02851563 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 1 condition, with Canavan Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02851563 reports a single indexed study location in Massachusetts, New York, Other.
Frequently Asked Questions
What is clinical trial NCT02851563 about?
NCT02851563 is a clinical study titled "A Natural History Study of Canavan Disease". The purpose of this study is to learn more about the natural history of Canavan disease
What is the current status of trial NCT02851563?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2016-05. Estimated completion is 2019-04.
What conditions does trial NCT02851563 study?
This clinical trial studies the following conditions: Canavan Disease.
Who is sponsoring clinical trial NCT02851563?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02851563 being conducted?
This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Canavan Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia